Cargando…

First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease

AIM: To compare the one-week clinical effects of single doses of dexlansoprazole and esomeprazole on grades A and B erosive esophagitis. METHODS: We enrolled 175 adult patients with gastroesophageal reflux disease (GERD). The patients were randomized in a 1:1 ratio into two sequence groups to define...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Chih-Ming, Kuo, Ming-Te, Hsu, Pin-I, Kuo, Chao-Hung, Tai, Wei-Chen, Yang, Shih-Cheng, Wu, Keng-Liang, Wang, Hsing-Ming, Yao, Chih-Chien, Tsai, Cheng-En, Wang, Yao-Kuang, Wang, Jiunn-Wei, Huang, Chih-Fang, Wu, Deng-Chyang, Chuah, Seng-Kee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2017
Materias:	Clinical Trials Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743510/ https://www.ncbi.nlm.nih.gov/pubmed/29307999 http://dx.doi.org/10.3748/wjg.v23.i47.8395

Ejemplares similares

Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial
por: Chiang, Hung-Hsien, et al.
Publicado: (2019)

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice
por: Hung, Kuo-Tung, et al.
Publicado: (2021)

A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial
por: Tai, Wei-Chen, et al.
Publicado: (2019)

Phase 4 Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole
por: Wu, Justin C Y, et al.
Publicado: (2020)

Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg
por: Kukulka, Michael, et al.
Publicado: (2011)

Managing gastroesophageal reflux disease – comparative efficacy and outcomes of dexlansoprazole MR
por: Frye, Jeanetta W, et al.
Publicado: (2015)

Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of Life
por: Takeshima, Fuminao, et al.
Publicado: (2015)

Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease
por: Kukulka, Michael, et al.
Publicado: (2014)

A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD)
por: Kalaitzakis, Evangelos, et al.
Publicado: (2007)

A Deep Learning Model for Classification of Endoscopic Gastroesophageal Reflux Disease
por: Wang, Chi-Chih, et al.
Publicado: (2021)

Current Pharmacological Management of Gastroesophageal Reflux Disease
por: Wang, Yao-Kuang, et al.
Publicado: (2013)

Correlation between Psychosomatic Assessment, Heart Rate Variability, and Refractory GERD: A Prospective Study in Patients with Acid Reflux Esophagitis
por: Wang, Hsin-Ming, et al.
Publicado: (2023)

Risk of Rebleeding and Mortality in Cirrhotic Patients with Peptic Ulcer Bleeding: A 12-Year Nationwide Cohort Study
por: Yang, Shih-Cheng, et al.
Publicado: (2017)

The Role of Adjuvant Acid Suppression on the Outcomes of Bleeding Esophageal Varices after Endoscopic Variceal Ligation
por: Wu, Cheng-Kun, et al.
Publicado: (2017)

Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
por: Kuo, Chia-Jung, et al.
Publicado: (2019)

Risk factors influencing the outcome of peptic ulcer bleeding in chronic kidney disease after initial endoscopic hemostasis: A nationwide cohort study
por: Liang, Chih-Ming, et al.
Publicado: (2016)

Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients – focus on esomeprazole
por: Tang, Raymond SY, et al.
Publicado: (2013)

First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus
por: Yao, Chih-Chien, et al.
Publicado: (2019)

Clinical utility of esomeprazole for treatment of gastroesophageal reflux disease in pediatric and adolescent patients
por: Cardile, Sabrina, et al.
Publicado: (2012)

First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan
por: Liang, Chih-Ming, et al.
Publicado: (2017)

The Association of Helicobacter pylori Eradication with the Occurrences of Chronic Kidney Diseases in Patients with Peptic Ulcer Diseases
por: Wang, Jiunn-Wei, et al.
Publicado: (2016)

Multiple bacterial infections increase the risk of hepatic encephalopathy in patients with cirrhosis
por: Yuan, Lan-Ting, et al.
Publicado: (2018)

Treatment and Cost of Hepatocellular Carcinoma: A Population-Based Cohort Study in Taiwan
por: Nguang, Seng-Howe, et al.
Publicado: (2018)

Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole
por: Mermelstein, Joseph, et al.
Publicado: (2016)

Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis
por: Xia, X. M., et al.
Publicado: (2013)

Endoscopic Management of Foreign Bodies in the Upper Gastrointestinal Tract of Adults
por: Yao, Chih-Chien, et al.
Publicado: (2015)

Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor – Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region
por: Goh, Khean Lee, et al.
Publicado: (2016)

Current advances in the diagnosis and management of gastroesophageal reflux disease
por: Liang, Shu-Wei, et al.
Publicado: (2022)

Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan
por: Hung, Tsung-Hsing, et al.
Publicado: (2017)

Bioavailability, safety, and pharmacodynamics of delayed-release dexlansoprazole administered as two 30 mg orally disintegrating tablets or one 60 mg capsule
por: Kukulka, Michael, et al.
Publicado: (2016)

The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance
por: Huang, Tzu-Hsin, et al.
Publicado: (2021)

Diagnosis and Management of Gastroesophageal Reflux Disease
por: Hsu, Ping-I, et al.
Publicado: (2013)

Efficacy and Safety of Esomeprazole for the Treatment of Reflux Symptoms in Patients with Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis
por: HOU, Mingxing, et al.
Publicado: (2020)

Association between Helicobacter pylori eradication and the risk of coronary heart diseases
por: Wang, Jiunn-Wei, et al.
Publicado: (2018)

Relationship between esomeprazole dose and timing to heartburn resolution in selected patients with gastroesophageal reflux disease
por: Orlando, Roy C, et al.
Publicado: (2010)

Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: focus on delayed-release esomeprazole
por: Guimarães, Elizabet V, et al.
Publicado: (2010)

Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan
por: Sakurai, Kouichi, et al.
Publicado: (2018)

The Efficacy and Safety of 14-day Rabeprazole Plus Amoxicillin High Dose Dual Therapy by Comparing to 14-day Rabeprazole-Containing Hybrid Therapy for the Naïve Helicobacter pylori Infection in Taiwan: A Randomized Controlled Trial
por: Tai, Wei-Chen, et al.
Publicado: (2023)

Risk of Periodontitis in Patients with Gastroesophageal Reflux Disease: A Nationwide Retrospective Cohort Study
por: Li, Xin, et al.
Publicado: (2022)

The efficacy of limited endoscopic sphincterotomy plus endoscopic papillary large balloon dilation for removal of large bile duct stones
por: Kuo, Chung-Mou, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aasl4damorj6ccsbkj3vmlvknl